Abiopharma

🔍 Kramer Andrea Anigati (Executive)

Company: Hamilton Lane INC (HLNE)

Report Date: 2026-05-29

Detailed Transactions and Holdings:

• Acquired 62 shares of Class A Common Stock at $84.89 per share (Direct)
  Date: 2026-03-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 82,524.00 | transaction_form_type: 5 | Footnotes: F1, F2
• Acquired 3,543 shares of Class A Common Stock (Direct)
  Date: 2026-05-29 | Code: A | equity_swap_involved: 0 | shares_owned_after: 86,067.00 | transaction_form_type: 4 | Footnotes: F4, F2
• Holds 0 shares of Class B Common Stock (Direct)
  Date: 2026-05-29 | Code: H | shares_owned_after: 135,970.00 | Footnotes: F5
• Holds 5,435 shares of Performance Stock (Derivative)
  Date: 2026-05-29 | Code: H | shares_owned_after: 5,435.00 | Footnotes: F6, F6, F6
• Holds 2,033 shares of Performance Stock (Derivative)
  Date: 2026-05-29 | Code: H | shares_owned_after: 2,033.00 | Footnotes: F7, F7, F7
• Holds 13,044 shares of Performance Stock (Derivative)
  Date: 2026-05-29 | Code: H | shares_owned_after: 13,044.00 | Footnotes: F8, F8, F8
• Holds 135,970 shares of Class B Units (Derivative)
  Date: 2026-05-29 | Code: H | shares_owned_after: 135,970.00 | Footnotes: F9, F9, F9, F10
• Holds 195,317 shares of Class C Units (Derivative)
  Date: 2026-05-29 | Code: H | shares_owned_after: 195,317.00 | Footnotes: F9, F9, F9, F10

Footnotes:

• F1: These shares of Class A common stock, $0.001 par value per share (the "Class A Shares") were acquired pursuant to the Issuer's Employee Share Purchase Plan in a transaction that was exempt under Rule 16b-3(d).
• F2: Includes unvested restricted stock granted under the Issuer's 2017 Equity Incentive Plan.
• F3: Includes 17,913 Class A Shares held in an IRA previously reported as indirectly owned.
• F4: Class A Shares issued to the reporting person pursuant to an award of restricted stock under the Issuer's 2017 Equity Incentive Plan. The award vests in four equal annual installments commencing on May 29, 2027.
• F5: The Class B common stock does not carry economic value beyond the right to receive the par value of such stock upon liquidation, dissolution or exchange of those shares. However, the Class B common stock entitles its holder to ten votes per share on every matter submitted to the Issuer's stockholders for a vote.
• F6: Each share of performance stock represents a contingent right to receive one Class A Share. The performance stock vests upon the Issuer's Class A Shares achieving a specified price per share. The performance period of the performance stock ends on September 16, 2031.
• F7: Each share of performance stock represents a contingent right to receive one Class A Share of the Issuer. The performance stock vests at the end of the performance period if the Issuer's Class A Shares achieves a specified growth rate of TSR over the performance period. The performance period of the performance stock ends on September 16, 2030.
• F8: Each share of performance stock represents a contingent right to receive one Class A Share. The performance stock vests upon the Issuer's Class A Shares achieving a specified price per share. The performance period of the performance stock ends on September 16, 2029.
• F9: Pursuant to an Exchange Agreement entered into in connection with a reorganization incident to the Issuer's initial public offering, the Class B Units and Class C Units of Hamilton Lane Advisors, L.L.C. ("HLA") are exchangeable, on a one-for-one basis, for Class A Shares or, at the Issuer's election, for cash. Upon exchange of a Class B Unit, the corresponding share of Class B common stock will be redeemed at par value and cancelled. The Class B Units and Class C Units of HLA do not have an expiration date.
• F10: Held on behalf of the reporting person by HL Management Investors, LLC.
• REMARKS: In addition to serving as an officer of the Issuer, the reporting person is a member of a group that beneficially owns more than 10% of the Issuer's Class A Shares.